PU21.02 Comparison of HIV incidence in simulated vaccine efficacy trials and observational cohorts using propensity scores in key populations in UgandaPublication OnlyNovel vaccine and other prevention approaches
PU21.03 Co-display of hyperstabilized HIV-1 envelope glycoprotein trimers on two-component protein nanoparticlesPublication OnlyNovel vaccine and other prevention approaches
PU21.03 Assessment of crosslinker suitability for fusion peptide conjugates as priming immunogens for an HIV-1 vaccinePublication OnlyNovel vaccine and other prevention approaches
PU21.06 DNA vs ChAd-vectored vaccines as priming vaccines in heterologous prime-boost regimens to increase HTI immunogenicity in micePublication OnlyNovel vaccine and other prevention approaches
PU21.08 Distinct classes of HIV-1 cross-clade neutralizing antibodies targeting fusion peptide elicited in mice by diverse immunization regimensPublication OnlyNovel vaccine and other prevention approaches
PU23.03 Being a part of the conversation: capacitating youth to participate in HIV prevention conversations using a digital citizen engagement platform in South AfricaPublication OnlyPolicy and advocacy
PU23.04 Lessons learned from the strategic agenda for key populations: Experiences from BrazilPublication OnlyPolicy and advocacy
PU24.01 Birth microbiota in HIV-exposed-uninfected infants cause changes in innate and adaptive immune compartments in a murine modelPublication OnlyPreclinical studies for HIV prevention
PU25.01 Social disclosures in relation to perceived HIV protection provided by the dapivirine vaginal ringPublication OnlyPreclinical studies for HIV prevention
PU25.02 Correlates of adherence to the dapivirine vaginal ring for HIV-1 preventionPublication OnlyProduct acceptability and adherence
seek-warrow-warrow-eseek-e61 - 70 of 444 items